Search Medical Condition
Please enter condition
Please choose location from dropdown

Neuss, Germany Clinical Trials

A listing of Neuss, Germany clinical trials actively recruiting patients volunteers.

RESULTS

Found (242) clinical trials

OPTIMAL>60 / DR. CHOP Improvement of Therapy of Elderly Patients With CD20+ DLBCL Using Rituximab Optimized and Liposomal Vincristine

Primary objective of study: "OPTIMAL>60 Less Favourable" Patients with less favourable prognosis: To test whether progression-free survival (PFS) can be improved by substituting conventional by liposomal vincristine; To test whether PFS can be improved by 12 optimised applications instead of 8 2-week applications of rituximab. "OPTIMAL>60 Favourable": Patients with favourable ...

Phase

0.0 miles

Learn More »

A Study of LY900014 in Elderly and Younger Adult Participants With Type 1 Diabetes Mellitus

The purpose of this study is to compare LY900014 with insulin lispro in elderly and younger adults with type 1 diabetes mellitus. Screening is required within 28 days prior to the start of the study. For each participant, the total duration of the clinical trial will be between 3 to ...

Phase

0.0 miles

Learn More »

A Trial to Investigate the Dose-linearity of BioChaperone Combo 75/25 and the Safety at Three Different Doses in Subjects With Type 2 Diabetes

This is a bicentric, double-blinded, randomised, four-period crossover phase 1 trial, using automated 30-hour euglycemic clamp in subjects with type 2 diabetes mellitus. Each subject will be randomly allocated to a sequence of four treatments, three single doses of BioChaperone® Combo 75/25 (0.6 U/kg, 0.8 U/kg or 1.0 U/kg) and ...

Phase

0.0 miles

Learn More »

A Study of Glucagon Nasal Powder in Participants With Type 1 Diabetes Mellitus

The purpose of this study is to compare a needle-free treatment of hypoglycemia with glucagon nasal powder (study drug) to a marketed glucagon administered by the intra-muscular (IM) route, in participants with type 1 diabetes mellitus (T1DM).

Phase

0.0 miles

Learn More »

A Meal Test Study of LY900014 in Participants With Type 1 Diabetes Mellitus

Two forms of insulin lispro (LY900014 and Humalog) and two forms of insulin aspart (NovoRapid and Fiasp) will be given to trial participants with diabetes mellitus type 1 by injection under the skin. The study will assess how fast the active ingredient (insulin lispro or insulin aspart) gets into the ...

Phase

0.0 miles

Learn More »

A Trial to Investigate Pharmacokinetics Pharmacodynamics Safety and Tolerability of BioChaperone Pramlintide Insulin in Patients With Type 1 Diabetes Mellitus

This is a single center, randomised, double-blind, active comparator controlled, three-period cross-over, single dose trial in subjects with type 1 diabetes mellitus. Each subject will be randomly allocated to a sequence of three treatments:(i) simultaneous administrations of BioChaperone pramlintide human insulin (BC Pram Ins) and placebo, (ii) simultaneous injections of ...

Phase

0.0 miles

Learn More »

Explorative Assessment of Biomarkers in Overweight and Obese Subjects

The pre-screening assessments are designed to characterize the metabolic risk profile / prediabetic status in an unselected population of overweight and obese volunteers, aiming to pre-select high risk and prediabetic subjects as a target population who may specifically profit from primary diabetes intervention (prevention) strategies.

Phase N/A

0.83 miles

Learn More »

Empagliflozin and Sympathetic Nerve Traffic

The drug empagliflozin is a selective oral inhibitor of the sodium-glucose co-transporter 2 (SGLT-2) in the kidney.On the market empagliflozin is approved for the treatment of type 2 Diabetes. The mechanism of action can be described as follows: SGLT-2 is responsible for 90% of the reabsorption of Glucose in the ...

Phase

0.83 miles

Learn More »

A Study to Demonstrate Bioequivalence Between Insulin Glulisine U300 and Insulin Glulisine U100 After a Single Subcutaneous Dose Using the Euglycemic Clamp Technique in Patients With Type 1 Diabetes Mellitus

The study duration per patient will be 18 to 62 days and will consist of a 4 to 28 days of screening period, a treatment period of 2 days, a washout between dosing occasions of 5-18 days, and follow up visit 7-14 days after last dosing.

Phase

0.83 miles

Learn More »

A Study of LY3209590 in Healthy Participants and Participants With Type 2 Diabetes

This trial is conducted to evaluate the safety of a study drug given by injection under the skin to healthy participants and participants with type 2 diabetes. It will also investigate how the body processes the study drug and the effect of the study drug on blood sugar levels. Information ...

Phase

0.83 miles

Learn More »